BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 6, 2026
Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
Substance use and poisoning, BioWorld Science RSS Feed RSS

Mosedipimod receives FDA orphan drug designation for ARS

Jan. 5, 2018

Addex and Indivior sign licensing and collaboration agreement for ADX-71441 to treat addiction

Jan. 3, 2018

Axsome Therapeutics and Duke University to collaborate on phase II study of AXS-05

Dec. 15, 2017

FDA approves once-monthly Sublocade to treat opioid use disorder

Dec. 1, 2017

FDA accepts, grants priority review to lofexidine NDA

Nov. 22, 2017

Orexo's Zubsolv approved for opioid dependence in Europe

Nov. 21, 2017

OX1 receptor antagonist C4X_3256 demonstrates efficacy in nicotine dependence rat model

Nov. 15, 2017

FDA committee recommends approval of Braeburn Pharmaceuticals' CAM-2038 for opioid use disorder

Nov. 2, 2017

FDA awards orphan drug status to Pluristem's PLX-R18 for ARS

Oct. 20, 2017

Otsuka submits NDA for nalmefene in Japan

Oct. 19, 2017
Previous 1 2 … 21 22 23 24 25 26 27 28 29 … 119 120 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • AI-generated image for brain organoid neural research

    CINP 2026: organoids reveal autism and addiction mechanisms

    BioWorld Science
    At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
  • Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

    BioWorld Science
    Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing